RETA

RETA

$20.00

Tri-Agonist PeptideResearch Compound A next-generation synthetic peptide engineered as a unimolecular agonist of three metabolic receptors simultaneously — GLP-1, GIP, and the glucagon receptor. Body composition — adipose tissue and visceral fat reduction in metabolic models Glycemic control — insulin sensitivity and pancreatic beta-cell function Energy expenditure — glucagon-mediated thermogenesis and basal metabolic rate Hepatic outcomes — liver lipid metabolism and steatosis research

Category:

Description

Retatrutide has been researched for metabolic disorders, primarily obesity and type 2 diabetes, due to its unique triple-agonist activity targeting:
• GLP-1 receptors (appetite suppression, glucose control)
• GIP receptors (insulin sensitivity, metabolic efficiency)
• Glucagon receptors (increased energy expenditure, fat loss)

Because of this combination, research has focused on significant weight reduction, improved glycemic control, and overall metabolic health compared to single- or dual-agonist compounds.
FOR RESEARCH ONLY

Tri-Agonist Peptide Research Compound
A next-generation synthetic peptide engineered as a unimolecular agonist of three metabolic receptors simultaneously — GLP-1, GIP, and the glucagon receptor.
  • Body composition — adipose tissue and visceral fat reduction in metabolic models
  • Glycemic control — insulin sensitivity and pancreatic beta-cell function
  • Energy expenditure — glucagon-mediated thermogenesis and basal metabolic rate
  • Hepatic outcomes — liver lipid metabolism and steatosis research

Reviews

There are no reviews yet.

Be the first to review “RETA”